All posts by imreal

US Fertility partner practice Shady Grove Fertility (SGF) welcomes Dr. Benjamin S. Harris to expand access to world-class fertility care in Richmond and Norfolk


Dr. Benjamin Harris is now scheduling new patient appointments at SGF’s Richmond and Norfolk locations.

“The foundation of our practice is based on doing what is best for our patients, promoting a strong patient-physician relationship, and promoting teamwork through collaborative care. We are constantly striving to improve the care we provide through education, research, and innovation.”

US Fertility, the nation’s largest partnership of physician-owned and physician-led top-tier fertility practices, welcomes Benjamin S. Harris, M.D., to SGF Richmond’s Stony Point and Henrico Doctors’-Forest locations as well as SGF Jones Institute’s Norfolk, Virginia, location. Dr. Harris is now scheduling new patient appointments.

“SGF puts the patient first,” shares Dr. Harris. “The foundation of our practice is based on doing what is best for our patients, promoting a strong patient-physician relationship, and promoting teamwork through collaborative care. We are constantly striving to improve the care we provide through education, research, and innovation. In doing so, we can enhance the experience of every single patient as we work toward achieving their fertility goals.”

To address the high demand in the region for top-quality fertility care, Dr. Harris will provide comprehensive fertility services, including:


  • fertility and ovarian reserve testing and diagnosis,
  • semen analysis,
  • hysterosalpingogram (HSG),
  • low-tech fertility treatment options such as intrauterine insemination (IUI),
  • in vitro fertilization (IVF),
  • donor egg, sperm, and embryo,
  • genetic screening and testing,
  • gestational carrier,
  • egg freezing,
  • reproductive surgical evaluation and management,
  • fertility preservation for patients with cancer, and
  • LGBTQ+ family building.

Dr. Harris is board certified in obstetrics and gynecology (OB/GYN) and board eligible in reproductive endocrinology and infertility (REI). Dr. Harris earned his medical degree and Master of Public Health from the University of North Carolina at Chapel Hill. He then completed his residency training in OB/GYN at Duke University Medical Center in Durham, North Carolina, where he was an Administrative Chief Resident. From there, Dr. Harris continued his training at Duke University Medical Center to complete his fellowship in REI.

As an avid researcher, Dr. Harris has contributed to numerous publications and presentations exploring such topics as fibroids, in vitro fertilization (IVF) protocols, reproductive epidemiology, and preimplantation genetic testing.    

“By welcoming Dr. Harris to the SGF physician team in Richmond and Norfolk, we’re able to expand access to those in need of fertility care in Richmond and Norfolk,” shares Erika B. Johnston-MacAnanny, M.D., Medical Director, SGF Richmond. “Dr. Harris’s dedication to working together with patients to achieve their goals through providing a collaborative and educational experience directly aligns with SGF’s mission to provide patient-centered fertility care.”

Patients may now schedule a new patient appointment with Dr. Harris by calling the SGF New Patient Center at 757-512-8547 or by completing this brief form.

About US Fertility

US Fertility is the nation’s largest partnership of physician-owned and physician-led top-tier fertility practices, offering comprehensive fertility-market-focused non-clinical, administrative, and technical platforms that help domestic and international practices improve patient outcomes and increase patient access. To learn more about partnership- or affiliate-status benefits, call 301-545-1308 or visit USFertility.com.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 50 locations, including the newest location in Raleigh, North Carolina, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Share article on social media or email:

Virtual Event Seeks to Equip and Empower Church Leaders on Mental Health Issues


Hands holding phone showing Church Mental Health Summit website

“Recent studies show that approximately 70 percent of church attendees will experience a trauma at some point, so the Church Mental Health Summit is a much-needed event,” says Dr. Jamie Aten, Co-Founder of Spiritual First Aid and Founder of the Humanitarian Disaster Institute at Wheaton College.

Spiritual First Aid will join forces with Hope Made Strong to present the Church Mental Health Summit. The free online summit for church leaders is a one-day event that will be available on-demand Monday, October 10th from 7:00 a.m. to 11:59 p.m. ET. Featured speakers include such prominent industry leaders in faith and mental health as Dr. Diane Langburg, Rich Villodas, Matthew Standford and many more.

“It’s an honor and privilege to collaborate with Spiritual First Aid in presenting a gathering of world-class speakers, pastors, and those with lived experience to equip the local church around the globe to support mental health in their churches and communities,” said Laura Howe, Founder of Hope Made Strong. “On-demand sessions will address mental health issues—from leadership wellbeing to strategies for pastoral care—that matter most to church leaders. This free event gives access to top-tier training for all.”

With the increase in mental health issues and the fact that people are more comfortable going to their church for support rather than to medical professionals, there is a greater need for ministry leaders to be equipped to support mental health needs.

By attending the Church Mental Health Summit, participants will be equipped with practical tools, engage with Biblically-based resources, and learn research-developed strategies to support mental health.

“We’re thrilled to partner with Hope Made Strong for the Church Mental Health Summit,” said Jamie Aten, co-founder of Spiritual First Aid and Founder and Executive Director of Wheaton College’s Humanitarian Disaster Institute. “It’s a much-needed event, since recent studies show that approximately 70 percent of church attendees will experience a trauma at some point in their life and more than 30 percent of pastors are at high or medium risk of burnout. The more we understand our emotional and spiritual struggles, the more likely we can take action to overcome them.”

The summit’s presentations are organized into 4 tracks: Global Health, Community Health, Church Health, and Leadership Health. Sessions are open to all participants for free on October 10th.

Participants can join the 50+ presenters for uplifting messages of hope and practical resources that will educate and encourage them to better serve their churches and care for their communities. Speakers include:


  • Dr. Jamie Ate n – Founder and Executive Director, Humanitarian Disaster Institute and Blanchard Chair, Humanitarian & Disaster Leadership at Wheaton College
  • Kent Annan – Director, Humanitarian and Disaster Leadership at Wheaton College’s Humanitarian Disaster Institute
  • Dr. Diane Langburg – Psychologist and international speaker
  • Dr. Karl Benzio – Medical Director, American Association of Christian Counselors (AACC)
  • Dr. Matthew Stanford – CEO, Hope and Healing Center & Institute
  • Laura Howe – Founder, Hope Made Strong
  • Cheryl Nembhard – Founder and Soul Care Coach, The Lighthouse Project
  • Dr. Gregg Jantz – Founder, The Center A Place of HOPE
  • Michelle Neihart – Licensed Professional Counselor, Your Mental Health Coach
  • Kobe Campbell – CEO & Lead Therapist, The Healing Circle
  • JS Park – Hospital chaplain, published author, and viral blogger
  • Brad Hoefs – Founder and Executive Director, Fresh Hope
  • Rich Villodas – Lead pastor, New Life Fellowship Church
  • Dr. Xavier Amador – President, LEAP Institute
  • Marty Sawyers – President & CEO, Full Strength Network
  • Steve Grcevich – President and Founder, Key Ministry
  • Daniel Whitehead – CEO, Sanctuary Mental Health Ministries
  • Kayla Stoecklein – Widow, Author, & Advocate, Rebuilding Beautiful
  • Thad Austin – Senior Director of Strategic Initiatives and Congregational Engagement, Duke University

Upon registering, summit-goers will receive access to a password-protected website with sessions that can be viewed on October 10th. For those who wish to view sessions after the event for staff training and volunteer onboarding, a $79 All-Access pass is required. Purchasing an all-access pass gives lifetime access to all the summit videos. Additional information and registration for the event are available at http://www.ChurchMentalHealthSummit.com.

Share article on social media or email:

MYOS CORP Announces Completion of Human Clinical Trial on the Impact of Fortetropin During Muscle Disuse in Healthy, Young Men


“Fortetropin has now shown efficacy in reducing Myostatin in 3 clinical studies. Very few nutritional supplements have been studied as rigorously as Fortetropin has been studied in human and preclinical studies,” stated Stuart Phillips, Ph.D., Professor of Kinesiology and Canada Research Chair.

MYOS CORP, a research-based, advanced nutrition company, announced the completion of a randomized, double blind, placebo-controlled human clinical trial conducted at McMaster University, Canada, that examined the impact of Fortetropin® on young men during periods of muscle disuse. The trial showed that Fortetropin supplementation prevented a rise in myostatin during a period of muscle disuse. Myostatin is a protein that arrests the growth and development of new muscle tissue. This finding is a significant addition to MYOS CORP’s robust portfolio of clinical research proving the muscle health efficacy of Fortetropin.

“The impact of Fortetropin® on serum myostatin concentrations in human subjects that participated in this clinical trial is intriguing,” stated Stuart Phillips, Ph.D., Professor of Kinesiology and Canada Research Chair, the Principal Investigator of this human clinical trial. “Fortetropin has now shown efficacy in reducing Myostatin in 3 clinical studies. Very few nutritional supplements have been studied as rigorously as Fortetropin® has been studied in human and preclinical studies. A safe, product that can prevent increases in serum myostatin has exciting potential, particularly in aging person’s rehab and recovery from injury.”

In order to assess the impact of Fortetropin on muscle disuse atrophy on human subjects, a model known as the unilateral leg immobilization model was utilized, which involved each subject wearing a knee brace for two weeks in order to simulate acute muscle inactivity. Subjects were required to consume their assigned supplement (Fortetropin® or macronutrient-matched placebo) for two weeks prior to the activity restriction phase of the study and continued to consume their assigned supplement for an additional two weeks during the recovery phase of the study.

One of the remarkable findings from this study was that while the subjects supplemented with the placebo did experience a statistically significant increase in plasma concentrations of myostatin during activity restriction, the subjects supplemented with Fortetropin® did not show any statistically significant changes in plasma myostatin concentrations.

“The results of this study are very exciting for MYOS CORP, and for the larger sports nutrition and age management fields,” said Joseph Mannello, MYOS CORP CEO. “Since the myostatin gene was discovered in 1997, many pharmaceutical companies have been actively engaged in developing myostatin inhibitors. Unfortunately, myostatin inhibitors sometimes fall into the wrong hands and are abused. These drugs can have very harmful side effects and should never be used without supervision from a physician. Fortetropin is a safe, natural product that is derived from fertilized, chicken egg yolk. It has tremendous potential to help humans stay active and healthy at every stage of life.”

The results observed in this human clinical trial with respect to myostatin mirror results that were published in 2020 by veterinary researchers at Kansas State University College of Veterinary Medicine. In this earlier study, 100 dogs were forced to undergo an 8-week period of activity restriction while recovering from a common veterinary surgical procedure known as tibial plateau leveling osteotomy (TPLO) which is performed to repair tears of the canine cruciate ligament (CCL). 50 dogs were supplemented with Fortetropin and 50 dogs were supplemented with a macronutrient matched placebo. Dogs that were supplemented with a macronutrient matched placebo experienced an average increase in myostatin concentration of ~10% after eight weeks had elapsed following surgery, while no statistically significant changes had been observed in dogs that were supplemented with Fortetropin®.

Research published in 2021 by researchers at the University of California, Berkeley revealed that older men and women (60-75 years old) that were supplemented with Fortetropin® experienced an increase in the rate of muscle protein synthesis (MPS) of ~18%. Maintaining muscle mass is crucial to enjoying a healthy and active lifestyle as adults age. Further, multiple peer-reviewed studies have reported that age-related muscle loss is associated with an increased risk of fall-related injuries. Falls can be devastating, particularly if they result in a bone fracture or a head injury.

“Fortetropin is now backed by seven peer-reviewed publications in reputable scientific journals,” said Mr. Mannello. “The completion of this most recent study at McMaster University represents the completion of MYOS’ third randomized, double blind, placebo-controlled human clinical study on Fortetropin. MYOS remains committed to pursuing rigorous scientific research as we build our Human Nutrition and Animal Health businesses.”

First discovered by researchers in 1997 at Johns Hopkins University, myostatin is a protein that arrests the growth and development of new muscle tissue]. A knockout strain of mice that were lacking myostatin were found to have approximately twice as much muscle mass as regular mice and were later referred as “mighty mice.” Blocking the activity of myostatin or that of its receptor, ActRIIB, using monoclonal antibodies has been a strategy that has been employed by multiple pharmaceutical and biotechnology companies over the last two decades to target musculoskeletal disorders such as sarcopenia and cachexia. Some studies have reported that plasma concentrations of myostatin increase with age.”

About MYOS CORP

MYOS CORP, “The Muscle Company®”, is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness and produces muscle health support products featuring Fortetropin under the names of Yolked®, MYOS Canine Muscle Formula®, (Regular & Vet Strength) and MYOS Feline Formula. For more information, please visit http://www.myoscorp.com.

Share article on social media or email:

Cameyo Recognized as a High Performer in G2’s Fall 2022 Reports for Both DaaS and VDI Categories


Badges for the six awards Cameyo earned in G2's Fall 2022 reports for both DaaS and VDI solutions.

“Especially now, when two of the oldest VDI and DaaS providers are being acquired and their futures are uncertain, many organizations are looking for alternatives. And the first place most IT decision makers turn for advice is to their peers in the industry, to learn from their experiences.”

Cameyo, the Virtual App Delivery (VAD) provider that enables ultra-secure Cloud Desktops so your people can be productive from anywhere, today announced that it has been recognized as a “High Performer” in both the Desktop-as-a-Service (DaaS) and Virtual Desktop Infrastructure (VDI) categories of the G2 Fall 2022 reports while also receiving several “best of” recognitions in those categories, including Best Estimated ROI. G2 Grid® Reports are based on the ratings and reviews of real end-users and reveal the solutions in each software category that have the most satisfied customers and largest market presence.

“The fact that G2’s ratings and reports are based on the real-life reviews and experiences of actual customers makes these recognitions so much more meaningful to us, because everything we do, we do with the goal of delighting and empowering our customers,” said Robb Henshaw, Co-Founder and CMO of Cameyo. “To have so many of our customers take the time to share their reviews of Cameyo with their peers, and to be ranked so highly – especially compared to many of the larger, legacy providers – is an absolute honor.”

Based on these customer reviews, Cameyo received the following recognitions in the G2 Fall 2022 reports:

Cameyo’s Virtual App Delivery (VAD) platform provides an ultra-secure, simple, and cost-effective cloud desktop solution for enabling organizations to deliver all their apps – legacy Windows, internal web, and SaaS – to any device without the need for legacy virtual desktops or VPNs. Unlike traditional VDI and DaaS solutions, Cameyo is a cloud-native virtualization solution that delivers any application to any device without delivering the Windows OS. Cameyo’s cloud desktop solution dramatically reduces cost & complexity while increasing security and providing a more seamless user experience.

“Especially now, when two of the oldest VDI and DaaS providers are being acquired and their futures are uncertain, many organizations are looking for alternatives. And the first place most IT decision makers turn for advice is to their peers in the industry, to learn from their experiences. So the G2 Fall 2022 reports for the VDI and DaaS categories are more relevant than ever, and we’re honored that our customers are so vocal about their love for our solution,” said Andrew Miller, Co-Founder and CEO at Cameyo.

About Cameyo

Cameyo’s Virtual App Delivery (VAD) platform provides an ultra-secure, simple, and cost-effective cloud desktop solution for enabling you to deliver all your apps – legacy Windows, internal web, and SaaS – to any device without the need for legacy virtual desktops or VPNs. Unlike traditional VDI and DaaS solutions, Cameyo is a cloud-native virtualization solution that delivers any application to any device without delivering the Windows OS. Cameyo’s cloud desktop solution dramatically reduces cost & complexity while increasing security and providing a more seamless user experience. Cameyo is a Chrome Enterprise Recommended solution, and hundreds of enterprises and organizations across all industries utilize Cameyo to deliver business-critical applications to hundreds of thousands of users worldwide. As of September 2022, Cameyo has a Net Promoter Score (NPS) of +83 with zero detractors – 100% of responding customers would recommend Cameyo to their peers. To learn more, visit cameyo.com.

Share article on social media or email:

YuMOVE, Joint Supplements for Dogs, Offers 5 Tips for Fall Fun with Your Senior Dog


Experience Fall Fun with Your Furry Friends

“To see the difference YuMOVE can make in your dog, YuMOVE is offering 40% off any YuMOVE hip and joint supplements for dogs using the code “FallFun40”one-time or for a monthly subscription at checkout.”

With the long days of summer behind us and the heat cooling off, fall is the perfect time to go outside, exercise and experience the great outdoors with your dog. YuMOVE, one of the best joint supplements for dogs¹ and The American Kennel Club’s official dog joint supplement, offers five fall tips to make the most of your autumn adventures with your furry friends.

1. Get outside and enjoy the fall weather. With cooler days, your dog should be excited to play in piles of leaves, adventure into the woods and smell the fragrant scents of the season.

2. Keep exercise regular and gentle. Aim for consistent, steady walks. Running, jumping and

twisting is more likely to cause joint stiffness.

3. Work up to longer walks, finding a route your pet loves. Slow and steady builds stamina. Great smells, interesting trees and spending time bonding with you.

4. Check to see if your dog has mobility concerns. Look for visible signs of stiffness, especially in the morning or after resting; slowing down on walks; reluctance to get out of bed or go up or down stairs; lethargy; grumpiness during or after walks, or when being petted.

5. Give your dog high-quality dog joint supplements, like YuMOVE, which will help give extra support for your dog’s joints and help their mobility.

YuMOVE, the UK’s #1 veterinary joint supplement,¹ already helps more than 2 million dogs per year live their most active life.² For the past 15 years, YuMOVE has been providing the highest quality dog joint supplement that is scientifically proven to work in just six weeks.³ There’s also a 60-Day Money-Back Guarantee,⁴ if you aren’t satisfied.

To see the difference YuMOVE can make in your dog, YuMOVE is offering 40% off any YuMOVEhip and joint supplements for dogs using the code “FallFun40” one-time or for a monthly subscription at checkout.

To learn more about how YuMOVE can help your dog, visit http://www.yumove.com.

¹Kynetec VetTrak August 2022. Sales of YuMOVE branded products through UK veterinary wholesalers.

²YuMOVE’s UK monthly brand tracker. Conducted by Stream Research.

³Study conducted by the Royal Veterinary College of London, UK. Data on file.

⁴For full terms and conditions see yumove.com/guarantee.

Share article on social media or email:

Erkki Ruoslahti wins America’s top biomedical research award


Erkki Ruoslahti, M.D., Ph.D., winner of the Albert Lasker Basic Medical Research Award

Erkki Ruoslahti, M.D., Ph.D., winner of the Albert Lasker Basic Medical Research Award

“I am honored to have been recognized by the Lasker Foundation for my work and thankful for Sanford Burnham Prebys Medical Discovery Institute for supporting me throughout much of my scientific career.”

Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor Emeritus at Sanford Burnham Prebys, has been announced as one of three winners of the Albert Lasker Basic Medical Research Award, the most prestigious American award for biomedical research, for his transformational research leading to the discovery of the cell adhesion receptors now known as integrins.

“Winning the Lasker Award is the dream of many American researchers working in biomedicine,” says Ruoslahti. “I am honored to have been recognized by the Lasker Foundation for my work and thankful for Sanford Burnham Prebys Medical Discovery Institute for supporting me throughout much of my scientific career.”

Ruoslahti shares the award with Richard O. Hynes from the Massachusetts Institute of Technology, and Timothy A. Springer from Boston Children’s Hospital and Harvard Medical School, for their independent discovery of the integrins. The award presentation is viewable at https://www.laskerawards.live/.

“Integrin-mediated cell adhesion guides cell migration and keeps our tissues together. Like molecular zip codes, it directs cells to the right location and keeps them attached there. Integrin activity in cancer cells is altered, which makes them capable of spreading to distant sites in the body, where they form metastases.”

Integrins are cell receptors that facilitate interactions between cells and with their environment. When integrins bind to their target molecules, they trigger biological actions such as cell attachment, movement, death or differentiation. Since the discovery, integrins have been studied in cancer (progression, metastasis, angiogenesis), sepsis, fibrosis, viral infections and autoimmunity. Integrin-targeting clinical trials—especially in cancer—are ongoing, and the approach remains promising.

In addition to helping open the integrin field, Ruoslahti’s discoveries led to the development of RGD-based drugs for vascular thrombosis and other diseases, including current efforts to direct drugs into tumors by making use of integrins expressed on tumor blood vessels but not on normal vessels.

Share article on social media or email:

Egnyte Once Again Recognized for Data Security and Governance Capabilities in G2 Fall 2022 Reports


Egnyte, the secure platform for content collaboration and governance, today announced it has been named a leader and No. 1 ranked vendor by software marketplace G2 in several of its Fall 2022 reports, based on user reviews and other online data as it relates to customer satisfaction and market presence.

“The Egnyte platform continues to receive high adoption as organizations navigate the new hybrid work environment amid increasing cyberattacks and rapidly-evolving data privacy regulations,” said Julie Giannini, Chief Customer Officer at Egnyte. “Listening to and meeting the needs of our customer base is of the utmost importance, which is why this recognition from G2 is very meaningful. I’ve been fortunate to spend valuable time recently with many of our customers as part of Egnyte’s Spark Sessions.”

Over the past quarter, Egnyte has continued to make significant product enhancements, such as improvements to snapshot-based ransomware recovery, a redesign of the Egnyte web application, and enhanced malware scanning and management capabilities to more effectively detect potential malware and remediate malware attacks.

Reviewers on G2 continue to recognize the platform for its ease of use and ability to protect data from cyber threats, with notable feedback this quarter including:


  • “Egnyte is a reliable cloud-based storage platform that is easy for end users and provides a robust set of features that add value without compromising security…[it] solves the need for remote access to files for employees that work remotely or in different offices by eliminating the need for VPN access.” – Vice President, Finance
  • “After 13 plus years with Egnyte, my data is as safe today as it was on day one… I love that I can access my data from anywhere in the world.” – Director of Operations
  • “[Egnyte] provides an excellent service to protect your sensitive data against threats and ransomware detection in the cloud. Also, they customize a collaborative environment.” – Senior Application Engineer

To learn more about Egnyte’s offerings and to get a look into the company’s roadmap, attend next month’s Spark Sessions. The in-person events in Chicago on Oct. 6 and Boston on Oct. 20 will feature customers and Egnyte executives including Co-Founder and Chief Strategy Officer Rajesh Ram and Chief Governance Officer Jeff Sizemore.

About Egnyte

Egnyte is the secure multi-cloud platform for content security and governance that enables organizations to better protect and collaborate on their most valuable content. Established in 2007, Egnyte has democratized cloud content security for more than 17,000 organizations, helping customers improve data security, maintain compliance, prevent and detect ransomware threats, and boost employee productivity on any app, any cloud, anywhere. For more information, visit http://www.egnyte.com.

Share article on social media or email:

XP Health Raises $17.1M Series A to Transform Vision Benefits for Insurance Carriers, Companies and Employees


XP Health Logo

“We have a game-changing offering for how people access and experience employee benefits – with an ultimate goal to positively impact hundreds of millions of lives through high-quality, accessible and affordable health benefits.”

XP Health, the company creating the first digital-first vision benefits platform, today announces a $17.1M Series A round led by HC9 Ventures, Valor Capital Group and ManchesterStory. Additional investors include Canvas Ventures, CameronVC, Core Innovation Capital, GSR Ventures, and Plug and Play, as well as high profile angels like Ken Goulet (former EVP Anthem), Kevin Hill (former regional CEO United Healthcare), Jeff Epstein (CFO of Oracle, partner at Bessemer Venture Partners) and Brett Rochkind (former managing partner General Atlantic). This expansion capital will bolster XP Health’s drive to reinvent how people experience vision benefits.

XP Health offers a high-quality, innovative vision care benefit that doubles the value of coverage while reducing costs by half for members. This recent fundraise follows a successful 2021 for the company, during which it raised $5.5 million and was named one of Fast Company’s Most Innovative Companies. Starting with just 30 clients last year, XP Health now services 1,500, including high-profile companies like Docusign, Chegg, Navistar, Sequoia Consulting, and strategic partners Guardian Life Insurance and The Health Benefit Alliance. All-in, XP Health covers more than 250,000 people.

Through its integrated supply chain, XP Health keeps costs low by removing the middlemen that add significant markups at several steps in the process. This business model has helped triple vision benefits coverage for employees while reducing their out-of-pocket costs by 80 percent, all while cutting employer eyewear claim costs by 40 percent. This model has also helped the company to grow their revenue by 9,300 percent since January 2021.

“This round of funding enables us to strengthen the platform’s functionality and provide a stellar consumer experience in the most affordable way to employers, insurance carriers, and employees,” said Antonio Moraes, Co-Founder, and CEO of XP Health and a former impact venture capital investor. “We have a game-changing offering for how people access and experience employee benefits – with an ultimate goal to positively impact hundreds of millions of lives through high-quality, accessible, and affordable health benefits.”

Vision coverage has remained static, complicated, expensive, and unsatisfying for decades. An estimated 93 million adults in the United States (about 25 percent of the population) are at high risk for serious vision loss, but only half visited an eye doctor in the past 12 months [1]. XP Health uses advanced technology to transform vision care into something people – whether they have 20/20 eyesight or need a prescription – are excited to use, and has a unique business model that lowers costs for all parties.

“The XP Health team is bringing some much-needed change to vision benefits. HC9 is excited to leverage our experience and network to help XP Health accelerate growth while improving eye health,” said Jon Gordon, General Partner of HC9 Ventures. “We know firsthand what it is like to operate and grow businesses that are driving health innovation, and XP Health is the perfect partner.”

“We believe that XP Health will fundamentally transform the future of vision benefits and are thrilled to contribute to their mission to innovate in the space,” said Michael Nicklas of Valor Capital Group. “XP Health is working hard towards expanding access to high quality vision care to millions of employees in the United States and we are proud to have backed the company since day one.”

“As an insuretech-focused investor, we know that quality benefit programs make a big difference in a company’s ability to attract and retain employees, which is especially important given the current state of the job market,” said David Miles of ManchesterStory. “XP Health is on a path to make vision care a ‘must have’ core employee benefit. Our confidence in XP Health’s founding team and their passion for the end-consumer made XP Health an investment opportunity we could not pass up.”

About XP Health

XP Health democratizes access to high-quality, delightful experiences in vision care that double coverage and reduce costs by half. It is the first modern vision platform focused on eye care and eyewear that can be used to enhance or replace existing vision plans, and uses artificial intelligence, augmented reality, and customer-centric design to create a stellar member experience. XP Health was named to the 2021 Fast Company list of the World’s Most Innovative Companies and over the past year has expanded from 30 to 1500+ customers, including Docusign, Palantir, Chegg, Sequoia Consulting, and strategic partner Guardian Life Insurance. To learn more visit xphealth.co.

About HC9

HC9 is an early-stage venture capital firm purpose-built to provide industry-specific expertise to emerging healthcare software and services companies. HC9’s unparalleled, deeply-engaged investor community of leading executives, entrepreneurs, and investors collectively has thousands of years of experience in all facets of healthcare. We leverage the power of that experience to support the founders that are shaping the future of healthcare. For more information, please visit http://www.hc9.vc.

About Valor Capital Group

Valor Capital Group is a global venture capital firm, focused on early-stage and growth equity investments. Currently, the Group has over $2 billion AUM, distributed across six funds. Valor pursues a cross-border strategy with a focus primarily in Brazil and throughout Latin America, as well as investing in international companies and helping them expand into the region. Since inception, the Firm has invested in over 100 companies, 20 of which are unicorns.

About ManchesterStory

ManchesterStory partners with world-class founders pursuing technological innovation in InsurTech and adjacent sectors. Focused on early-stage start-ups, ManchesterStory leads venture capital investments to fund growth while also connecting them with leading financial services companies across North America and beyond.

[1] https://www.cdc.gov/visionhealth/resources/publications/high-risk-vision-loss.html#:~:text=In%202017%2C%20approximately%2093%20million,exam%20in%20the%20last%20year.

Share article on social media or email:

EnSoftek’s DrCloudEHR™ is selected by Clackamas County to support behavioral healthcare community needs


News Image

CCBHD is excited to adopt EnSoftek’s DrCloudEHR solution. We believe it will streamline our services and enhance our clients’ experience. Taking a client-centered approach is a goal we and EnSoftek share, and we look forward to a successful collaboration. Mary Rumbaugh, CCBHD Director

EnSoftek Inc., the provider of the purpose-built DrCloudEHR™ solution to the Health and Human Services market, is happy to share that, Clackamas County’s Behavioral Health Division has selected the DrCloudEHR solution to replace its legacy health records system.

“Our partnership with Clackamas County Behavioral Health represents our continued commitment to connecting consumers with available care providers through the use of technology to achieve strong results for our partners.” said Al Lechner General Manager of EnSoftek Inc. Ensoftek welcomes this strategic partnership as we journey together making each patient encounter a success.

About Clackamas County Behavioral Health Division

Clackamas County Behavioral Health (CCBHD) is a division of the Department of Health, Housing and Human Services. Its purpose is to work collaboratively with community partners to ensure the provision of coordination, support, outreach, education, and treatment services to Clackamas County residents so they can achieve their mental health and addiction recovery goals.

CCBHD is responsible for 24-7 crisis response to Clackamas County residents experiencing behavioral health distress. This includes the 24-7 crisis line and mobile outreach team. In addition, they investigate allegations of abuse for adults in mental health services and conduct investigations for involuntarily committed individuals. They provide intensive care coordination for children and adults on the Oregon Health Plan (Health Share of Oregon and Trillium Community Health Plan) including those individuals at the Oregon State Hospital.

About EnSoftek Inc.

EnSoftek empowers health and human services organizations to provide better outcomes for their clients and modernize their business operations with DrCloudEHR. Our industry-leading, cloud-based EHR solution maximizes clinician success, improves engagement, and simplifies work across the entire care continuum, including tracking treatment outcomes. The EnSoftek community includes addiction treatment, mental health, I/DD, long-term care companies, government agencies, and non-profit organizations.

Follow us on Twitter, LinkedIn, and Facebook.

http://www.drcloudehr.com; http://www.ensoftek.com

Share article on social media or email:

LAUNCHER.SOLUTIONS Expands Integration with The Work NumberⓇ by Equifax


Today, LAUNCHER.SOLUTIONS (“Launcher”), a technology provider specializing in loan originations, announced an expanded integration of Launcher’s appTRAKER Loan Origination System (“LOS”) with The Work Number® from Equifax, the industry-leading centralized commercial repository of income and employment information in the U.S.

appTRAKER LOS was designed for lenders looking for a more efficient way to consume data to originate loans and build a stronger portfolio. This expansion between appTRAKER LOS and The Work Number offers additional products for lenders:

  • The Work Number Select – Gold


Provides all employment and income information such as Employer Name, Employment Status, Rate of Pay etc.


Provides the status of an employment record on The Work Number database.

  • Employment & Income Verifications


Instant access to data direct from employers and payroll providers.

Lenders utilizing appTRAKER LOS are able to automatically access employment and income information, helping to reduce time and errors that can occur in a manual process.

“We are proud to deepen our relationship with Equifax by offering additional products from The Work Number,” said Nikh Nath, President of LAUNCHER.SOLUTIONS. “Our integrations with third party data providers are invaluable to our lenders. The verifications provided by The Work Number can be run automatically or manually, during the underwriting phase or the verification phase. The integration allows the quality and flexibility needed to book loans quickly and efficiently.”

Auto lenders need the ability to automatically verify employment information on potential borrowers for a faster, lower friction borrower experience. With more than 573 million income and employment records from 2.5 million employers across a variety of industries, The Work Number allows lenders utilizing the appTRAKER Loan Origination System to have the information that they need at their fingertips to make smarter, faster credit decisions.

About LAUNCHER.SOLUTIONS

LAUNCHER.SOLUTIONS is a technology products and services company built on the foundation of care, understanding, innovation, and speed. It specializes in loan origination for subprime/nearprime automotive lending institutions, regional banks, and credit unions. Its product offerings include appTRAKERTM LOS for indirect automotive lending as well as consumer direct lending and leasing, myDEALER.CARE dealer relationship management system, and myACCOUNT.CARE customer self-service and communication solution. LAUNCHER.SOLUTIONS has service offerings aimed at helping its clients with projects related to data analytics, data integration, telephony, and custom web development. Learn more at http://www.launcher.solutions/ or call 877.5LNCHER. Follow LAUNCHER.SOLUTIONS on LinkedIn at https://www.linkedin.com/company/launcher.solutions.

Share article on social media or email: